 AstraZeneca AZN, 0.48 AZN, 0.42 is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma MREO, 16.03 , The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialists partners, which include Novartis NVS, 0.60 , OncXerna and Ultragenyx RARE, -1.36. 